aBLA Filing Intelligence & Biosimilar Opportunity

Loqtorzi

Toripalimab-Tpzi

Anticancer

IV Infusion

Loqtorzi is an IV antibody used alongside other treatments for recurrent or metastatic nasopharyngeal carcinoma. It helps the immune system recognize and attack cancer cells.

Approval Date

27-Oct-23

Data Exclusivity Expiry

27-Oct-27

Market Exclusivity Expiry

27-Oct-35

Commercial snapshot

Market performance & projections

Revenue ($M)

329

CAGR (%)

-0.1715

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

115

2028

140

2029

155

2030

165

2031

175

2032

185

Molecule profile

Details & specifications

Molecule

Toripalimab-Tpzi

Innovator

COHERUS BIOSCIENCES

Dosage Form

IV Infusion

Strength

40 mg/mL

Therapeutic Category

Anticancer

Usage

To treat recurrent or metastatic nasopharyngeal carcinoma when used together with or following other therapies

Good to know

Frequently asked questions

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.